Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-76fb5796d-dfsvx Total loading time: 0 Render date: 2024-04-26T12:44:04.443Z Has data issue: false hasContentIssue false

Chapter 21 - Neuroterrorism and Drug Overdose in the Neurocritical Care Unit

Published online by Cambridge University Press:  24 July 2019

By
John J. Lewin ,
Mohit Datta  and
Geoffrey S. F. Ling
Edited by
Michel T. Torbey
Michel T. Torbey
Affiliation:
Ohio State University
Get access

Summary

Knowledge of proper clinical management of drug overdose and chemical and biological toxin exposure is important for the neurocritical care specialist. Many of the common offenders principally affect the central nervous system (CNS). Even those that do not will lead to a severely incapacitated state when overdosed such that the afflicted patient will require critical care in an intensive care unit (ICU).

Type
Chapter
Information
Neurocritical Care , pp. 254 - 268
Publisher: Cambridge University Press
Print publication year: 2019

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Chyka, PA, Seger, D, Krenzelok, EP, Vale, JA; American Academy of Clinical, Toxicology, European Association of Poisons Centres and Clinical Toxicologists. (2005). Position paper: single-dose activated charcoal. Clin Toxicol, 43: 61–87.Google Scholar
American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. (1999). Position statement and practice guidelines on the use of multi-dose activated charcoal in the treatment of acute poisoning. Clin Toxicol, 37(6): 731–751.Google Scholar
Proudfoot, AT, Krenzelok, EP, Vale, JA. (2004). Position paper on urine alkalinization. J Toxicol Clin Toxicol, 42: 1–26.Google Scholar
Charness, ME, Simon, RP. (1989). Ethanol and the nervous system. N Engl J Med, 321: 442–454.CrossRefGoogle ScholarPubMed
Hardman, J, Limbird, L, Gilman, A. (2005). Goodman & Gilmans: The Pharmacological Basis of Therapeutics, 10th edn. New York: McGraw-Hill.Google Scholar
Haynes, JF Jr. (2006). Medical management of adolescent drug overdoses. Adolesc Med Clin, 17: 353–379.Google ScholarPubMed
van Dorp, EL, Yassen, A, Dahan, A. (2007). Naloxone treatment in opioid addiction: the risks and benefits. Expert Opin Drug Safety, 6: 125–132.Google Scholar
Powner, DJ, Hartwell, EA, Hoots, WK. (2005). Counteracting the effects of anticoagulants and antiplatelet agents during neurosurgical emergencies. Neurosurgery, 57: 823–831.CrossRefGoogle ScholarPubMed
Garcia, DA, Baglin, TP, Weitz, JI, Sanama, MM. (2012). Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th edn. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 141: e24S–e43S.Google Scholar
Hirsh, J, Anand, SS, Halperin, JL, Fuster, V; American Heart Association. (2001). AHA scientific statement: guide to anticoagulant therapy: Heparin. A statement for healthcare professionals from the American Heart Association. Arterioscl Thrombos Vasc Biol, 21: E9–9.Google ScholarPubMed
Laposata, M, Green, D, Van Cott, EM, et al. (1998). College of American Pathologists conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med, 122: 799–807.Google Scholar
Ageno, W, Gallus, AS, Wittkowsky, A, et al. (2012). Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th edn. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 141(2 Suppl): e44S–e88S.Google Scholar
Kcentra® [package insert]. Kankakee, IL: CSL Behring LLC, 2014. www.fda.gov/ucm/groups/fdagov-public/@fdagov-bio-gen/documents/document/ucm350239.pdf. (accessed December 2018).Google Scholar
Nutescu, EA, Dager, WE, Kalus, JS, Lewin, JJ 3rd, Cipolle, MD. (2013). Management of bleeding and reversal strategies for oral anticoagulants: clinical practice considerations. Am J Health Syst Pharm, 70(21): 1914–1929.Google Scholar
Mohammed Ebid, AH, Abdel-Rahman, HM. (2001). Pharmacokinetics of phenobarbital during certain enhanced elimination modalities to evaluate their clinical efficacy in management of drug overdose. Ther Drug Monit, 23: 209–216.CrossRefGoogle ScholarPubMed
Amrein, R, Hetzel, W, Hartmann, D, Lorscheid, T. (1988). Clinical pharmacology of flumazenil. Eur J Anaesthesiol Suppl, 2: 65–80.Google Scholar
Kerr, GW, McGuffie, AC, Wilkie, S. (2001). Tricyclic antidepressant overdose: a review. Emerg Med J, 18(4): 236–241.CrossRefGoogle ScholarPubMed
Office of the Surgeon General. (1997). Textbook of Military Medicine. Washington, DC: The Office of the Surgeon General.Google Scholar
Fletcher, D. A brief history of the Tylenol poisonings. http://content.time.com/time/nation/article/0,8599,1878063,00.html (accessed December 2018).Google Scholar
Woods, JB. (2005). USAMRIID’s Medical Management of Biological Casualties Handbook, 6th edn. Frederick, MD: U.S. Army Medical Research Institute of Infectious Diseases.Google Scholar
Wampler, RA, Blanton, TS. (2001). The national security archive. www.gwu.edu/~nsarchiv/NSAEBB/NSAEBB61/ (Accessed December 2018).Google Scholar
The University of Pittsburgh hospitalized patients supercourse. www.publichealth.pitt.edu/supercourse/SupercoursePPT/11011–12001/276,14, Hospitalized patients (AUM Shinrikyo).Google Scholar
Kristof, ND. (1997). Japanese cult said to have planned nerve gas attacks in U.S. www.nytimes.com/1997/03/23/world/japanese-cult-said-to-have-planned-nerve-gas-attacks-in-us.html. (Accessed December 2018).Google Scholar
Woods, JB. (2005). USAMRIID’s Medical Management of Biological Casualties Handbook, 6th edn. Frederick, MD: U.S. Army Medical Research Institute of Infectious Diseases.Google Scholar
Meyer, MA. (2003). Neurologic complications of anthrax: a review of the literature. Arch Neurol, 60: 483–488.Google Scholar
Osterbauer, PJ, Dobbs, MR. (2005). Neurobiological weapons. Neurol Clin, 23: 599–621.Google Scholar
Mytle, N, Hopkins, RJ, Malkevich, NV, et al. (2013). Evaluation of intravenous anthrax immune globulin for treatment of inhalation anthrax. Antimicrob Agents Chemother, 57(11): 5684–5692.Google Scholar
FDA approves raxibacumab to treat inhalational anthrax. (2012). www.infectioncontroltoday.com/bacterial/fda-approves-raxibacumab-treat-inhalational-anthrax (accessed December 2018).Google Scholar
Mazumdar, S. (2009). Raxibacumab. MAbs, 1(6): 531–538.Google Scholar
FDA anti-infective drugs advisory committee meeting: raxibacumab. Nov 2012. Available at: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM326185.pdf. (Accessed July 10, 2014)Google Scholar
Arnon, SS, Schechter, R, Inglesby, TV, et al. (2001). Botulinum toxin as a biological weapon: medical and public health management. [erratum appears in JAMA 2001;285(16):2081]. JAMA 285: 1059–1070.CrossRefGoogle ScholarPubMed
Martin, CO, Adams, HP Jr. (2003). Neurological aspects of biological and chemical terrorism: a review for neurologists. Arch Neurol, 60: 21–25.CrossRefGoogle ScholarPubMed
BAT, Botulsim Antitoxin heptavalent (A, B, C, D, E, F, G) – (Equine)® [package insert]. Cangene Corporation: Winnipeg, Manitoba; Kankakee, IL; 2014. www.fda.gov/downloads/%E2%80%A6/UCM345147.pdf. (accessed December 2012).Google Scholar
Infant Botulism Treatment and Prevention Program (IBTPP). (2018). www.infantbotulism.org/physician/obtain.php. (accessed December 2018).Google Scholar
Smith, DL, Ayres, JG, Blair, I, et al. (1993). A large Q fever outbreak in the West Midlands: Clinical aspects. Respir Med, 87: 509–516.CrossRefGoogle Scholar
Henderson, DA, Inglesby, TV, Bartlett, JG, et al. (1999). Smallpox as a biological weapon: medical and public health management. working group on civilian biodefense. JAMA, 281: 2127–2137.Google Scholar
Pennington, H. (2003). Smallpox and bioterrorism. Bull WHO, 81: 762–767.Google Scholar
Division of Vector-Borne Infectious Diseases. (n.d.). Arboviral encephalitis. wwwn.cdc.gov/nndss/conditions/arboviral-encephalitis/ (accessed December 2018).Google Scholar
Benzer, TI. Toxicity, tetrodotoxin. (2018). www.emedicine.com/emerg/topic576.htm (accessed December 2018).Google Scholar
Pavlin, JA. (1999). Epidemiology of bioterrorism. Emerg Infect Dis, 5:528–530.Google Scholar
Broughton, E. (2005). The Bhopal disaster and its aftermath: a review. Environ Health, 4: 6.Google Scholar
Newmark, J. (2004). The birth of nerve agent warfare: lessons from Syed Abbas Foroutan. Neurology, 62: 1590–1596.Google Scholar
Hurst, G, Tuorinsky, S. (2007). Medical Management of Chemical Casualties Handbook, 4th edn. Aberdeen Proving Ground, MD: US Army Medical Research Institute of Chemical Defense.Google Scholar
Jett, DA. (2007). Neurological aspects of chemical terrorism. Ann Neurol, 61: 9–13.Google Scholar
Shih, TM, Duniho, SM, McDonough, JH. (2003). Control of nerve agent-induced seizures is critical for neuroprotection and survival. Toxicol Appl Pharmacol, 188: 69–80.Google Scholar
Singh, S, Chaudhry, D, Behera, D, Gupta, D, Jindal, SK. (2001). Aggressive atropinisation and continuous pralidoxime (2-PAM) infusion in patients with severe organophosphate poisoning: experience of a northwest Indian hospital. Hum Exp Toxicol, 20: 15–18.CrossRefGoogle ScholarPubMed
Hantson, P, Duprez, T. (2006). The value of morphological neuroimaging after acute exposure to toxic substances. Toxicol Rev, 25: 87–98.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×